Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Endocrinology  |  Nephrology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Diabetic Kidney Disease Clinical Trials

A listing of Diabetic Kidney Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (11) clinical trials

Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria

Despite optimal treatment with renin-angiotensin-aldosterone-system (RAAS) inhibitors, many patients with non-diabetic kidney disease show progressive kidney function loss, which is associated with high residual proteinuria. Novel treatment strategies are therefore required to further decrease proteinuria and to slow kidney function decline. Dapagliflozin is a sodium-glucose transport (SGLT2) inhibitor and inhibits ...

Phase

Effect of Oral Supplementation With Curcumin in Patients With Proteinuric Diabetic Kidney Disease

Diabetic Kidney Disease (DKD) represents the fist cause of end-stage kidney disease in Mexico and the world, and it is characterized by the presence of hyperfiltration, glomerular hypertrophy, tubular albuminuria and mesangial matrix expansion, mainly by the oxidative stress and the pro-inflammatory state. Current treatments are limited on controlling proteinuria ...

Phase

Exercise Study Testing Enhanced Energetics of Muscle Mitochondria in CKD

Sarcopenia is a common complication of chronic kidney disease. Sarcopenia is defined by decreased muscle mass or function and is central to the frailty phenotype that is associated disability, hospitalization, and death. Sarcopenia is a common and devastating complication of chronic kidney disease (CKD). The investigators and others have demonstrated ...

Phase

Hyperbaric Oxygen Therapy for Renal Regeneration in Diabetic Nephropathy

Scientific background Diabetic Kidney Disease (DKD): The kidneys, which are an important target for diabetic induced damage, contribute a lot to this burden. Diabetic nephropathy (DN) is the most common cause of end-stage kidney disease worldwide, associated with increased morbidity and mortality in patients with diabetes. The pathogenesis of DKD ...

Phase

EMPRA (EMPagliflozin and RAs in Kidney Disease)

This study will be a prospective, clinical pilot study in CKD patients to show whether Empagliflozin in addition to ACEi treatment significantly increases Ang 1-7 levels compared to ACEi treatment alone. Null and alternative hypotheses: H0: Empagliflozin in addition to ACEi treatment does not increase Ang 1-7 levels more than ...

Phase

Effect of an L-Carnitine-Containing Peritoneal Dialysis (PD) Solution on Insulin Sensitivity in Diabetic Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)

The current study is initiated in order to assess the impact of a PD solution containing L-carnitine on insulin sensitivity evaluated by measuring insulin requirement.

Phase

A Study of Autologous Neo-Kidney Augment (NKA) in Patients With Diabetic Chronic Kidney Disease

NKA is made from expanded autologous selected renal cells obtained from each individual subject's kidney biopsy. All subjects enrolled will receive NKA. Subjects will receive their first NKA injection as soon as the NKA product is manufactured and shipped to the clinical site. After 3 months (+12 weeks), a second ...

Phase

Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria

The primary objective of this study is to assess the effect of 2 dose levels of TMX-049 on urinary albumin excretion in subjects with Type 2 diabetes and albuminuria (a urinary albumin-to-creatinine ratio (UACR) 200 to 3000 mg/g and an estimated glomerular filtration rate (eGFR) 30 ml/min/1.73m2). Effects of each ...

Phase

A Double-blind Study to Investigate Efficacy Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease

The purpose of the trial is the analysis of safety and efficacy of the chymase inhibitor BAY1142524 at a dose of 25 mg BID in comparison to placebo using a 6 months treatment period in type II diabetic patients with a clinical diagnosis of diabetic kidney disease. BAY1142524 or placebo ...

Phase

A Study of Autologous Neo-Kidney Augment (NKA) in Type 2 Diabetics With Chronic Kidney Disease

NKA is made from expanded autologous selected renal cells obtained from each individual subject's kidney biopsy. To manufacture NKA, biopsy tissue from each enrolled subject will be sent to Twin City Bio LLC, in whose facilities renal cells will be expanded and SRC selected. SRC will be formulated in a ...

Phase